Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07391215Phase 1Recruiting

5G-PEARL: Paxalisib in Malignant Brain Tumours

Role: collaborator

NCT06630260Phase 1Recruiting

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Role: collaborator

NCT06632236Phase 1Recruiting

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Role: collaborator

NCT05504772Recruiting

Precision Medicine for Every Child With Cancer

Role: collaborator

All 4 trials loaded